$1.600
+0.107 (+6.67%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
NIKI 相似圖表分析預測
Alphio's NIKI stock price prediction model matches the current Niki BioSolutions, Inc. tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.59 (-0.43%). The 1-week path is $1.55 (-3.29%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 Niki BioSolutions, Inc. 股票嗎?
Niki Biosolutions, Inc. is not a good buy right now due to its extremely low price and negative financial indicators. The current price is $1.60, which is significantly down from its 52-week high of $70.00, indicating a staggering 97.71% year-to-date decline. Additionally, the company has a negative PE ratio of -1.35 and a current ratio of only 0.56, suggesting liquidity issues. The main risk is the company's ongoing losses, as it reported a net income loss of $613,995 in the most recent quarter.
NIKI 股價於 Friday 收在 $1.60,此前上漲 +6.67%
Niki BioSolutions, Inc. (NIKI) last closed at $1.6, gaining +6.67%. These facts feed the 1-day and 1-week NIKI price prediction above.
預測驅動因素
Niki BioSolutions, Inc.(NIKI)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
相似圖表形態
近期走勢與 NIKI 最接近的股票,依相似度排序。
NIKI 季節性分析
相關文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。